Lorlatinib/lorlatinib: the latest progress and clinical application of third-generation ALK inhibitors

Lorlatinib is not a fourth-generation ALK-targeted drug, but a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) with high efficacy and brain-penetrating ability. It exhibits broad efficacy against most resistance mutations that emerged during prior treatment with crizotinib and second-generation ALK TKIs.

Lorlatinib plays an important role in anti-tumor treatment with its unique oral administration method and excellentALK activity inhibition ability. It specifically binds to the ATP binding site of ALK, thereby inhibiting its kinase activity and interfering with downstream signaling, ultimately inducing tumor cell apoptosis and inhibiting its growth. It is worth mentioning that compared with previous ALK inhibitors, lorlatinib exhibits stronger blood-brain barrier penetration and brings more significant therapeutic effects to patients with brain metastases. Research data shows that lorlatinib is excellent at controlling tumor proliferation and delaying disease progression.

The safety assessment of lorlatinib was based on data from 295 patients treated with the recommended dose (100 mg daily). Most of the related adverse reactions are mild to moderate, with hypercholesterolemia, hypertriglyceridemia, edema, peripheral neuropathy, and central nervous system effects being the most commonly reported symptoms. Fortunately, these adverse reactions can be effectively managed by adjusting the drug dose and/or using standard supportive medical treatment, and permanent discontinuation due to adverse reactions is rare.

In summary, lorlatinib, as an advanced third-generationALK inhibitor, provides a new treatment option for patients with ALK-positive metastatic non-small cell lung cancer who have previously received second-generation ALK TKI treatment. According to the official approval of the U.S. Food and Drug Administration (FDA), the once-daily 100 mg lorlatinib treatment regimen undoubtedly brings a brighter treatment prospect to patients with ALK-positive non-small cell lung cancer.